Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
NCT01557296 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2018-11-06
Summary
The objective of the study is in subjects with Insulin Treated Diabetes Mellitus type 1 or 2 and gastroparesis:
* validate radiopaque markers with fluoroscopy with gastric scintigraphy method
* study the difference of metabolic control including the frequents of hypoglycaemia, gastrointestinal symptoms, quality of life and nutrition state during dietary treatment of food of small particle size compared with food of large particle size
* validate the radiopaque markers method and measurement of the blood glucose and gastrointestinal symptoms after a test meal, against the gastric scintigraphy
* determine if the function of gastric emptying can be improved after intervention
Conditions
- Diabetic Gastroparesis
Interventions
- DIETARY_SUPPLEMENT
-
dietary treatment: food of small particle size
Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
- RADIATION
-
Validate X-ray diagnostic method.
Follow 20 radiopaque markers throw the ventricle by X-ray.
- OTHER
-
Can the motility be improved
Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
- BIOLOGICAL
-
postprandial plasma glucose
Measure the blood glucose response and gastrointestinal symptoms after a test meal
Sponsors & Collaborators
-
Göteborg University
lead OTHER
Principal Investigators
-
Magnus Simrén, M.D., Ph.D. · Inst of Medicine, Sahlgrenska Academy, Göteborg University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-09-30
- Primary Completion
- 2014-03-31
- Completion
- 2014-03-31
Countries
- Sweden
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
NCT03544229 ·Status: COMPLETED ·Phase: PHASE2
-
Acupuncture for Diabetic Gastroparesis
NCT00470795 ·Status: SUSPENDED ·Phase: PHASE3
-
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
NCT00390975 ·Status: TERMINATED ·Phase: PHASE4
-
Gastroparesis in type2 Diabetic Patient
NCT05584462 ·Status: NOT_YET_RECRUITING
-
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890 ·Status: UNKNOWN ·Phase: NA
-
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT01079624 ·Status: COMPLETED ·Phase: PHASE1
-
Trial Investigating Efficacy of G-POEM
NCT05830994 ·Status: UNKNOWN ·Phase: NA
-
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
NCT00537719 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Gastric Emptying on Blood Glucose Profile of Type 1 Diabetes Mellitus and Its Therapeutic Strategies
NCT06173934 ·Status: RECRUITING ·Phase: NA
-
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
NCT02289846 ·Status: COMPLETED ·Phase: PHASE2
-
Postprandial Gut Hormone Responses in Patients With Type 1 Diabetes Mellitus
NCT04430946 ·Status: UNKNOWN ·Phase: NA
-
A Scintigraphy Study in Adults With Diabetic Gastroparesis
NCT04208698 ·Status: TERMINATED ·Phase: PHASE2
-
Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.
NCT02225951 ·Status: TERMINATED ·Phase: NA
-
GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans
NCT02731664 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
NCT00861809 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR)
NCT06695962 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00673751 ·Status: UNKNOWN ·Phase: NA
-
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes
NCT02669524 ·Status: COMPLETED ·Phase: NA
-
Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes
NCT01517490 ·Status: UNKNOWN
-
Low Glycemic Index Diet in Patients With Type 1 Diabetes
NCT01184703 ·Status: COMPLETED ·Phase: PHASE3
-
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
NCT03241303 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy
NCT05875636 ·Status: COMPLETED
-
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging
NCT04352738 ·Status: COMPLETED
-
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
NCT04964388 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of GLP-1 Agonists on Gastric Volume
NCT05854979 ·Status: COMPLETED